louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT01291966: Efficacy of a Intervention to Reduce Medication Errors and Improve Adherence
Official title: Efficacy of a Intervention to Reduce Medication Errors and Therapeutic Failure in Patients Over 65 Years Polypharmacy
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Medication Adherence
Patient Compliance
Keywords: medication errors
Patient Compliance
patient safety
polypharmacy
Lead sponsor: Hospital Universitario Reina Sofia de Cordoba
Sponsor class: OTHER_GOV
Collaborators: name: Sociedad Andaluza de Medicina Familiar y Comunitaria
name: Sociedad Española de Medicina Familiar y Comunitaria
First posted: 2011-02-09
Enrollment: 154
Sex: ALL
Minimum age (years): 65
Standard ages: OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The purpose of this study is to demonstrate that an intervention based on the motivational interview directed to patients with polypharmacy to improve the Therapeutic Adherence and to reduce the errors of Medication in major measure that the habitual intervention.


Eligibility criteria: Inclusion Criteria:

* Patients with polypharmacy (5 or more medicines)
* That detects to them a problem of Therapeutic Adherence
* That agree to take part in the study

Exclusion Criteria:

* Immobilized patients or with an index of Barthel lower than 60 points
* Incapable to fulfill ABVD
* Patients with cognitive deterioration
* Patients with diagnosis of ictus in the last 6 months
* That has been admitted to hospital 2 or more times in the last year Institutionalized patients

Primary outcomes:
measure: medication errors in the patients
timeFrame: Baseline, 1, 3 and 6 months
Secondary outcomes:
measure: Percentage of adherence
timeFrame: Baseline and 6 months
Other outcomes:
Locations:
city: Córdoba
country: Spain
facility: Unidad Docente de Medicina Familiar y Comunitaria
Study officials:
affiliation: Andalusian Health Service
name: Luis A Perula, PH D
role: PRINCIPAL_INVESTIGATOR
References:
citation: Moral RR, Torres LA, Ortega LP, Larumbe MC, Villalobos AR, Garcia JA, Rejano JM; Collaborative Group ATEM-AP Study. Effectiveness of motivational interviewing to improve therapeutic adherence in patients over 65 years old with chronic diseases: A cluster randomized clinical trial in primary care. Patient Educ Couns. 2015 Aug;98(8):977-83. doi: 10.1016/j.pec.2015.03.008. Epub 2015 Mar 18.
citation: Perula de Torres LA, Pulido Ortega L, Perula de Torres C, Gonzalez Lama J, Olaya Caro I, Ruiz Moral R; Grupo corporativo Estudio ATEM-AP. [Efficacy of motivational interviewing for reducing medication errors in chronic patients over 65 years with polypharmacy: Results of a cluster randomized trial]. Med Clin (Barc). 2014 Oct 21;143(8):341-8. doi: 10.1016/j.medcli.2013.07.032. Epub 2013 Dec 28. Spanish.
Clinical trial NCT07009366: Comparison of Methods of Weaning From Nasal CPAP in Preterm Infants: A Randomized Controlled Trial
Official title: Comparison of Methods of Weaning From Nasal CPAP in Preterm Infants: A Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Respiratory Distress Syndrome, Newborn
Lead sponsor: RESnTEC, Institute of Research
Sponsor class: OTHER
First posted: 2025-06-06
Enrollment: 75
Sex: ALL
Minimum age (years): 1
Maximum age (years): 24
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: This study aimed to determine the efficacy of different NCPAP weaning strategies in pre-term infants presenting with respiratory distress, and ultimately establishing the best method to withdraw from NCPAP.

Detailed description: Pakistan, as well as other developing countries, lacks data regarding the weaning protocol of NCPAP. Ascertaining the best weaning method that could facilitate a shorter duration on nasal CPAP and the least length of hospital stay is very much needed. Findings of this study would help clinicians to achieve better outcomes for the patients receiving nasal CPAP.

Eligibility criteria: Inclusion Criteria:

* Preterm infants
* Any gender
* Low birth weight
* Gestational ages between 28 to below 37 weeks
* Presented with respiratory distress
* Neonates with radiological findings suggestive of respiratory distress, congenital pneumonia/sepsis, or transient tachypnea of the newborn (TTN)

Exclusion Criteria:

* Complex congenital abnormalities like diaphragmatic hernia, CNS malformations, intrapartum-related hypoxia, or congenital heart disease.
* Intraventricular hemorrhage grade III or IV or low APGAR scores (\<4 or 5 at 5 minutes)

Primary outcomes:
measure: Successful weaning
timeFrame: 4 days
Secondary outcomes:
measure: Comparison of total days on NCPAP
timeFrame: 4 days
measure: Hospital stay
timeFrame: 25 days
Other outcomes:
Locations:
city: Karachi
country: Pakistan
facility: Ziauddin University
state: Sindh
Study officials:
affiliation: Ziauddin University Karachi
name: Rabia Asif
role: PRINCIPAL_INVESTIGATOR
affiliation: Ziauddin University Karachi
name: Heena Rais, FCPS
role: STUDY_DIRECTOR
References:
Clinical trial NCT01130766: Asymptomatic Brain Metastasis in Non-small Cell Lung Cancer (NSCLC)
Official title: Randomized Phase III Trial of Stereotactic Radiosurgery (SRS) Versus Observation for Patients With Asymptomatic Cerebral Oligo-metastases in Non-small Cell Lung Cancer (NSCLC)
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE3
Conditions: Non-small Cell Lung Cancer
Keywords: Non-small Cell Lung Cancer
Asymptomatic brain metastasis
Stereotactic radiosurgery (SRS)
Lead sponsor: Samsung Medical Center
Sponsor class: OTHER
First posted: 2010-05-26
Enrollment: 176
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The prognosis of NSCLC patients with asymptomatic brain metastasis, who are not treated with SRS or WBRT has not been fully investigated yet. This randomized phase III trial is conducted to determine the exact role of SRS in NSCLC patients with asymptomatic oligo brain metastases whether early treatment with SRS would improve survival even in patients with asymptomatic brain metastasis.


Eligibility criteria: Inclusion Criteria:

* Histologically confirmed non-small cell lung cancer with synchronous brain metastases (diagnosis of brain lesion before or within 2 months from diagnosis of the primary site tumor)

  * One to 4 intraparenchymal brain metastases by contrast-enhanced MRI, meeting the following criteria:

    1. Well circumscribed tumor(s) with brain edema Grade 0-1
    2. Maximum diameter ≤ 3.0 cm

       * No prior complete resection of all known brain metastases or RT ④ No leptomeningeal metastases by MRI or cerebrospinal fluid evaluation

         * Patients without any symptoms or signs from brain metastases (RTOG neurologic functions status of 0) ⑥ Age, 18 and over ⑦ ECOG performance status 0-1 ⑧ Written informed consent

       Exclusion Criteria:
* severe co-morbid illness and/or active infections ② pregnant or lactating women

  * RTOG neurologic function status of 1\~4 ④ Uncontrollable extracranial metastases

Primary outcomes:
measure: Overall survival
timeFrame: 36 months
Secondary outcomes:
measure: time to CNS progression
timeFrame: 36 months
measure: time to symptomatic brain metastasis
timeFrame: 36 months
measure: quality of life
timeFrame: 36 months
measure: cause of death (neurologic vs. others)
timeFrame: 36 months
measure: neurocognitive function
timeFrame: 36 months
Other outcomes:
Locations:
city: Seoul,
country: Korea, Republic of
facility: Samsung Medical Center
Study officials:
affiliation: Samsung Medical Center
name: Myungju Ahn, M.D., Ph.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06905366: Cognitive Function and Postoperative Quality of Recovery
Official title: Association Between Cognitive Function and Postoperative Quality of Recovery - a Prospective Cohort Study
Study type: OBSERVATIONAL
Overall status: NOT_YET_RECRUITING
Conditions: Perioperative Neurocognitive Disorders
Postoperative Quality of Recovery
Keywords: cognitive function
Lead sponsor: Universitätsklinikum Hamburg-Eppendorf
Sponsor class: OTHER
First posted: 2025-04-01
Enrollment: 140
Sex: ALL
Minimum age (years): 65
Standard ages: OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: patients aged 65 years or older, who are scheduled for elective non-cardiac surgery

Brief summary: This study aims to assess the association between perioperative cognitive function and postoperative quality of recovery.


Eligibility criteria: Inclusion Criteria:

* elective non-cardiac surgery
* age ≥65 years
* duration of surgery ≥60 years

Exclusion Criteria:

* inability to give informed consent

Primary outcomes:
measure: QoR-15GE
timeFrame: first postoperative day
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT01411566: Clinical Intervention Psychosis and Addiction
Official title: Evaluation of an Integrative Therapeutic Concept for Schizophrenic Patients With Comorbid Substance Use Disorder
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: EARLY_PHASE1
Conditions: Psychosis
Substance Abuse
Keywords: KLIPS
Lead sponsor: University of Cologne
Sponsor class: OTHER
First posted: 2011-08-08
Enrollment: 122
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to evaluate an integrative therapeutic concept for schizophrenic patients with comorbid substance use disorder.


Eligibility criteria: Inclusion Criteria:

* Schizophrenia
* Addiction
* Written statement of agreement
* Majority

Exclusion Criteria:

* Acute psychosis
* Further neuropsychiatric disorder

Primary outcomes:
measure: Substance use
timeFrame: one year
measure: Substance use
timeFrame: 3 months
measure: Substance use
timeFrame: 6 months
measure: Change in drug use motivation
timeFrame: 3 months
measure: Change in drug use motivation
timeFrame: 6 months
measure: Change in drug use motivation
timeFrame: 1 year
Secondary outcomes:
Other outcomes:
Locations:
city: Cologne
country: Germany
facility: LVR Clinic Cologne - Academic Clinic of the University of Cologne
Study officials:
affiliation: University of Cologne
name: Joerg Daumann, PhD
role: STUDY_CHAIR
References:
Clinical trial NCT00990366: Treatment of Biliary Obstruction Using Biliary Stent With or Without Antireflux Valve
Official title: Treatment of Biliary Obstruction Using Biliary Stent With or Without Antireflux Valve
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: Biliary Obstruction
Cholangitis
Keywords: antireflux valve
biliary obstruction
cholangitis
biliary stent
Lead sponsor: Turku University Hospital
Sponsor class: OTHER_GOV
First posted: 2009-10-06
Enrollment: 15
Sex: ALL
Minimum age (years): 18
Maximum age (years): 89
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Biliary obstruction can be relieved by biliary stent. Ascending infection of biliary passage (cholangitis) causes hospitalization and obstruction of stents. Reflux of intestinal fluids through a stent is thought to be one of the causes of cholangitis. Stents with antireflux valves are designed to reduce the reflux from the bowel. The purpose of the study is to investigate prospectively whether it is possible to reduce the amount of infection and thus obstruction of biliary stent by using a stent with an antireflux valve compared to a normal stent without an antireflux valve.


Eligibility criteria: Inclusion Criteria:

* age 18-89
* biliary obstruction in the lower two thirds of the choledochus

Exclusion Criteria:

* allergy to contrast media
* future pancreaticoduodenectomy
* refusal from the study
* previous stent

Primary outcomes:
measure: patency of a biliary stent
timeFrame: one year
Secondary outcomes:
measure: Cholangitis
timeFrame: one year
Other outcomes:
Locations:
city: Turku
country: Finland
facility: Turku University Hospital
Study officials:
affiliation: Turku University Hospital
name: Paulina Salminen, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05462366: Omics Sequencing of Specimen Derived From Mother-Infant-Pairs
Official title: Omics Sequencing of Specimen Derived From Mother-Infant-Pairs
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Healthy
Breast-milk Collection
Feces
Lead sponsor: Zhujiang Hospital
Sponsor class: OTHER
First posted: 2022-07-18
Enrollment: 100
Sex: ALL
Maximum age (years): 40
Standard ages: CHILD
ADULT
Accepts healthy volunteers: yes
Observational model: FAMILY_BASED
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: This study intends to screen pregnant women in the Obstetrics and Gynecology Center of Zhujiang Hospital, Southern Medical University, and preliminarily recruit subjects that meet the inclusion criteria according to clinical diagnosis and auxiliary examination results. According to the specific conditions of vaginal delivery and post-birth newborns, the final inclusion of healthy pregnant women and newborns will be determined, and a total of 40-50 mother-infant-pairs will be recruited

Brief summary: The investigators aim to collect breast-milk and feces from the participants, and apply culture techniques as well as omics sequencing technology to probe into the microbial and metabolomic signature of the specimens.


Eligibility criteria: Inclusion Criteria:

* healthy pregnant women aged between 20y and 40y.
* Vaginal birth
* BMI\<23.5 before pregnancy
* Infants' birth weight, between 2500g and 4000g.

Exclusion Criteria:

* gestational diabetes
* diagnosis of depressive disorder during pregnancy
* gestational hypertension
* diagnosis of other diseases during pregnancy
* Under probiotics or antibiotic treatment from 3 months prior to pregnancy till 3 months after delivery
* histrory of smoking and drinking alcohol
* history of diarrhea from 3 months prior to pregnancy till 3 months after delivery

Primary outcomes:
measure: Compare the omics differences of the specimens between the experimental and control groups
timeFrame: 2021.7.1-2026.12.30
measure: Compare the microbial feature differences of the specimens between the experimental and control groups
timeFrame: 2021.7.1-2026.12.30
Secondary outcomes:
measure: Compare the health status differences between the experimental and control groups
timeFrame: 2021.7.1-2026.12.30
Other outcomes:
Locations:
city: Guangzhou
country: China
facility: Zhujiang Hospital
state: Guangdong
Study officials:
References:
Clinical trial NCT04720066: Hip POCUS for the Diagnosis of Pediatric Hip Effusion.
Official title: Accuracy of Point of Care Ultrasound (POCUS) for the Diagnosis of Hip Effusion Among Children in the Pediatric Emergency Department
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Hip Effusion
Keywords: Hip Effusion, point of care sonography, pediatric,
Lead sponsor: Meir Medical Center
Sponsor class: OTHER
First posted: 2021-01-22
Enrollment: 100
Sex: ALL
Minimum age (years): 0
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: * pediatric patients (age 0-18 years) presenting to the PED with the complaint of a limp or a lower limb pain

Brief summary: Limping is a common complaint among children presenting in the Pediatric ED the evaluation of a limp among infants and toddlers is challenging doe to the lack of specific history and the difficulty in locating the pain - therefore hip sonography is frequently used in the clinical evaluation of these children.

Sonographic examination for the diagnosis of hip effusion is routinely performed by the radiologist, however, since the integration of Point of care Ultrasound (POCUS) as part of the clinical evaluation of children in the ED in many application - Hip pocus is frequently performed by pediatric Emergency Medicine physicians.

The existing data on hip POCUS is scarce and comprised of small uncontrolled studies.

We aimed to examine the specificity and sensitivity of hip Pocus performed by pediatric emergency physicians by comparing it to the scan performed by the radiologist.

the primary outcome measurement is the ability of the POCUS exam to identify or rule out the existence of hip effusion as demonstrated in the formal radiological Ultrasound scan.

Detailed description: Children (0-18 years) presenting to the PED in Meir medical center with limp pain (not due to trauma) or a limp are recruited After consenting to participate in the study and completing the registration process the primary physician who is an approved researcher by the institutes IRB will perform hip POCUS as part of the clinical evaluation and will record his interpretation in the medical file. A formal ultrasound scan will be perfumed additionally by the radiologist. Both examination will be reviewed by POCUS lead physician and the Pediatric radiologist.

The patient's clinical and epidemiological data will be extracted from the electronic chart.

Eligibility criteria: Inclusion Criteria: pediatric patients presenting to the PED with the complaint of a limp or a lower limb pain

-

Exclusion Criteria:

* trauma patients
* patients with an obvious diagnosis other than pain resulting from the hip joint on their physical examination.

Primary outcomes:
measure: accuracy of POCUS examination for the detection of hip effusion among limping children
timeFrame: both examination are performed during the same 1 day ED visit.
Secondary outcomes:
Other outcomes:
Locations:
city: Kfar Saba
country: Israel
facility: Ayelet Shles
Study officials:
References:
Clinical trial NCT04820166: The Effect of Monitoring PVP on Clinical Outcomes in Patients With PH
Official title: The Effect of Monitoring Portal Venous Pressure on Clinical Outcomes in Patients With Portal Hypertension: a Prospective, Single-center, Observational Study
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Portal Hypertension
Lead sponsor: Nanfang Hospital, Southern Medical University
Sponsor class: OTHER
First posted: 2021-03-29
Enrollment: 200
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: patients with portal hypertension

Brief summary: The complications associated with portal hypertension in cirrhosis are the main cause of death in patients with cirrhosis. The level of portal venous pressure is closely related to the prognosis of patients. HVPG (hepatic venous pressure gradient) is the "gold standard" for predicting portal venous pressure and an important indicator for evaluating the efficacy of NSBBS. However, monitoring HVPG has many limitations，and the clinical application is also limited to a certain extent. Therefore, this study intends to clarify the guiding value of monitoring portal venous pressure in the clinical diagnosis and treatment of portal hypertension patients through a single-center, prospective and observational study. Therefore, this study intends to clarify the guiding value of monitoring portal venous pressure in the clinical diagnosis and treatment of portal hypertension patients through a single-center, prospective and observational study. At the same time, to explore the correlation between HVPG and PPG in cirrhosis patients at different stages and different etiologies, and to evaluate the role of spleen stiffness in predicting the severity of esophageal and gastric varices in patients with portal hypertension, and to find biomarkers to predict the risk of complications related to portal hypertension.


Eligibility criteria: Inclusion Criteria:

* With chronic liver disease
* Age 18-80 years
* Patients who require a portal pressure measurement at the discretion of the treating physician
* Voluntarily signed informed consent

Exclusion Criteria:

* With serious cardiopulmonary disease or other diseases affect survival
* With severe renal dysfunction
* Concomitant portal vein cavernous degeneration or extensive portal vein thrombosis
* Women who are planning to become pregnant or who are pregnant or breastfeeding
* The researcher judged that it was not suitable to participate in this study

Primary outcomes:
measure: Gastroesophageal varices bleeding
timeFrame: three years
measure: Ascites
timeFrame: three years
measure: Hepatic encephalopathy
timeFrame: three years
Secondary outcomes:
measure: Death or final follow-up time (3 years)
timeFrame: three years
Other outcomes:
Locations:
city: Guangzhou
country: China
facility: Nanfang Hospital
state: Guangdong
Study officials:
References:
Clinical trial NCT01394666: Non-interventional Treatment Patterns Study in Chronic Phase Chronic Myelogenous Leukemia (CP-CML)
Official title: Treatment Patterns and Associated Outcomes in Chronic Phase (CP) Chronic Myelogenous Leukemia (CML) Patients Who Fail Imatinib 400 mg Daily
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Chronic Myeloid Leukemia
Lead sponsor: Bristol-Myers Squibb
Sponsor class: INDUSTRY
First posted: 2011-07-14
Enrollment: 150
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Primary care clinic, academic and community oncology centers

Brief summary: The purpose of this study is to evaluate treatment patterns and associated outcomes for CP-CML patients who fail Imatinib 400 mg daily in a real-world setting.

Detailed description: Time Perspective: Retrospective and Prospective

Eligibility criteria: For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com.

Inclusion Criteria:

* Adult patients (18 years or older) in Chronic phase CML patients who have been treated with Imatinib 400 mg and have failed.

Primary outcomes:
measure: Complete Cytogenic Response (CCyR) for CP-CML patients who failed Imatinib 400 mg daily
timeFrame: At 3 months post treatment change
measure: Complete Cytogenic Response (CCyR) for CP-CML patients who failed Imatinib 400 mg daily
timeFrame: At 6 months post treatment change
measure: Complete Cytogenic Response (CCyR) for CP-CML patients who failed Imatinib 400 mg daily
timeFrame: At 12 months post treatment change
Secondary outcomes:
measure: Prognostic factors (clinical and demographic characteristics) that influence treatment selection for CP-CML patients who fail imatinib 400 mg daily
timeFrame: Baseline
measure: Prognostic factors (clinical and demographic characteristics) that influence treatment selection for CP-CML patients who fail imatinib 400 mg daily
timeFrame: 3 months after start of treatment
measure: Prognostic factors (clinical and demographic characteristics) that influence treatment selection for CP-CML patients who fail imatinib 400 mg daily
timeFrame: 6 months after start of treatment
measure: Prognostic factors (clinical and demographic characteristics) that influence treatment selection for CP-CML patients who fail imatinib 400 mg daily
timeFrame: 12 months after start of treatment
measure: Best response rates achieved by patients if no CCyR
timeFrame: Baseline
measure: Best response rates achieved by patients if no CCyR
timeFrame: 3 months after start of treatment
measure: Best response rates achieved by patients if no CCyR
timeFrame: 6 months after start of treatment
measure: Best response rates achieved by patients if no CCyR
timeFrame: 12 months after start of treatment
Other outcomes:
Locations:
Study officials:
affiliation: Bristol-Myers Squibb
name: Bristol-Myers Squibb
role: STUDY_DIRECTOR
References: